Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: Results of a phase I/II trial

A nonrandomized trial was undertaken to evaluate the combination of didanosine and interferon-alpha (IFN-alpha) in human immunodeficiency virus (HIV)-infected patients, Thirty-six volunteers with >200 x 10(6) CD4 cells/L received didanosine (one 100-, 250-, or 375-mg sachet twice daily) for at least 6 weeks, following which IFN-alpha (1, 5, 10, or 15 MU/day) was begun. Didanosine (one 375-mg sachet twice daily) was substituted for zidovudine in 14 additional patients who had received IFN-alpha and zidovudine for 7-45 months. Thirty-five patients completed the 34-week study, Clinical or chemical pancreatitis was the most common (6 patients) dose-limiting toxicity, CD4 cell counts increased with didanosine but declined following the addition of IFN-alpha; CD4 cell percents tended to increase and remain elevated. Thus, combination therapy with didanosine and IFN-alpha can be safely administered to patients with HIV infection, The clinical benefit of this combination therapy will require further evaluation.